RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
+15.45%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$1.22B
AUM Growth
+$1.22B
(+9.6%)
Cap. Flow
+$27.5M
Cap. Flow
% of AUM
2.25%
Top 10 Holdings %
Top 10 Hldgs %
47.36%
Holding
68
New
14
Increased
14
Reduced
24
Closed
13
Top Buys
| 1 |
AGN
Allergan plc
AGN
|
$41.5M |
| 2 |
HCA Healthcare
HCA
|
$35.4M |
| 3 |
AbbVie
ABBV
|
$34.3M |
| 4 |
Cigna
CI
|
$32.2M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
$28.4M |
Top Sells
| 1 |
ENDP
Endo International plc
ENDP
|
$50.3M |
| 2 |
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
|
$41.9M |
| 3 |
Ultragenyx Pharmaceutical
RARE
|
$27.2M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$25.3M |
| 5 |
TVTY
Tivity Health, Inc. Common Stock
TVTY
|
$21.2M |
Sector Composition
| 1 | Healthcare | 85.69% |
| 2 | Financials | 2.76% |
| 3 | Communication Services | 1.41% |
| 4 | Technology | 1.32% |
| 5 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
GWPH
26
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $17.9M | 1.47% |
146,027
+26,913
| +23% | +$3.31M |
|
27
Incyte
INCY
$17B
| $17.2M | 1.41% |
+164,995
| New | +$17.2M |
|
|
MODN
28
DELISTED
MODEL N, INC.
MODN
| $17.2M | 1.41% |
1,443,278
-18,400
| -1% | -$219K |
|
|
OXFD
29
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $16.8M | 1.38% |
1,212,892
-202,590
| -14% | -$2.81M |
|
|
CSLT
30
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
| $16.2M | 1.32% |
1,984,631
-351,867
| -15% | -$2.86M |
|
|
ZSPH
31
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
| $15.9M | 1.3% |
302,988
-102,700
| -25% | -$5.38M |
|
|
CASC
32
DELISTED
Cascadian Therapeutics, Inc.
CASC
| $15.6M | 1.28% |
+4,164,878
| New | +$15.6M |
|
|
CIVI
33
DELISTED
Civitas Solutions, Inc.
CIVI
| $14M | 1.15% |
657,693
-221,792
| -25% | -$4.73M |
|
34
Fate Therapeutics
FATE
$115M
| $13M | 1.06% |
+2,007,446
| New | +$13M |
|
35
DaVita
DVA
$9.72B
| $11.1M | 0.91% |
140,191
-125,667
| -47% | -$9.99M |
|
|
BPMC
36
DELISTED
Blueprint Medicines
BPMC
| $9.67M | 0.79% |
+378,235
| New | +$9.67M |
|
37
Adverum Biotechnologies
ADVM
$68.2M
| $8.73M | 0.72% |
537,282
+116,149
| +28% | +$1.89M |
|
38
ProQR Therapeutics
PRQR
$256M
| $8.61M | 0.71% |
516,690
-234,481
| -31% | -$3.91M |
|
|
GNCA
39
DELISTED
Genocea Biosciences, Inc.
GNCA
| $8.56M | 0.7% |
623,519
-173,381
| -22% | -$2.38M |
|
40
Standard BioTools
LAB
$493M
| $8.43M | 0.69% |
348,237
-214,200
| -38% | -$5.18M |
|
41
Cerus
CERS
$251M
| $8.32M | 0.68% |
1,603,427
-44,300
| -3% | -$230K |
|
|
TRIV
42
DELISTED
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
| $7.84M | 0.64% |
1,464,563
-124,060
| -8% | -$664K |
|
|
PTLA
43
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $6.96M | 0.57% |
+152,700
| New | +$6.96M |
|
|
44
Ultragenyx Pharmaceutical
RARE
$3.04B
| $6.9M | 0.57% |
67,425
-265,175
| -80% | -$27.2M |
|
|
BLCM
45
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| $5.07M | 0.42% |
238,121
-207,100
| -47% | -$4.41M |
|
|
CCXI
46
DELISTED
ChemoCentryx, Inc.
CCXI
| $3.92M | 0.32% |
476,293
+458,793
| +2,622% | +$3.78M |
|
47
Carisma Therapeutics
CARM
$15.5M
| $3.56M | 0.29% |
1,261,260
+1,021,260
| +426% | +$2.88M |
|
|
FLXN
48
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $3.12M | 0.26% |
142,483
-47,141
| -25% | -$1.03M |
|
|
SIOX
49
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $3.06M | 0.25% |
+150,000
| New | +$3.06M |
|
|
NVTA
50
DELISTED
Invitae Corporation
NVTA
| $2.56M | 0.21% |
181,224
-603,907
| -77% | -$8.54M |
|